Circulation,
Journal Year:
2022,
Volume and Issue:
145(18)
Published: April 1, 2022
The
"2022
AHA/ACC/HFSA
Guideline
for
the
Management
of
Heart
Failure"
replaces
"2013
ACCF/AHA
and
"2017
ACC/AHA/HFSA
Focused
Update
2013
Failure."
2022
guideline
is
intended
to
provide
patient-centric
recommendations
clinicians
prevent,
diagnose,
manage
patients
with
heart
failure.
Circulation,
Journal Year:
2023,
Volume and Issue:
147(20), P. 1534 - 1553
Published: May 15, 2023
Sarcopenia
is
the
loss
of
muscle
strength,
mass,
and
function,
which
often
exacerbated
by
chronic
comorbidities
including
cardiovascular
diseases,
kidney
disease,
cancer.
associated
with
faster
progression
diseases
higher
risk
mortality,
falls,
reduced
quality
life,
particularly
among
older
adults.
Although
pathophysiologic
mechanisms
are
complex,
broad
underlying
cause
sarcopenia
includes
an
imbalance
between
anabolic
catabolic
homeostasis
or
without
neuronal
degeneration.
The
intrinsic
molecular
aging,
illness,
malnutrition,
immobility
development
sarcopenia.
Screening
testing
for
may
be
important
those
disease
states.
Early
recognition
because
it
can
provide
opportunity
interventions
to
reverse
delay
disorder,
ultimately
impact
outcomes.
Relying
on
body
mass
index
not
useful
screening
many
patients
will
have
sarcopenic
obesity,
a
phenotype
cardiac
patients.
In
this
review,
we
aimed
to:
(1)
definition
within
context
wasting
disorders;
(2)
summarize
associations
different
diseases;
(3)
highlight
approach
diagnostic
evaluation;
(4)
discuss
management
strategies
sarcopenia;
(5)
outline
key
gaps
in
knowledge
implications
future
field.
Circulation,
Journal Year:
2021,
Volume and Issue:
145(6), P. 437 - 447
Published: Nov. 13, 2021
Chronic
kidney
disease
and
type
2
diabetes
are
independently
associated
with
heart
failure
(HF),
a
leading
cause
of
morbidity
mortality.
In
the
FIDELIO-DKD
(Finerenone
in
Reducing
Kidney
Failure
Disease
Progression
Diabetic
Disease)
FIGARO-DKD
Cardiovascular
Mortality
Morbidity
trials,
finerenone
(a
selective,
nonsteroidal
mineralocorticoid
receptor
antagonist)
improved
cardiovascular
outcomes
patients
albuminuric
chronic
diabetes.
These
prespecified
analyses
from
assessed
effect
on
clinically
important
HF
outcomes.
Circulation,
Journal Year:
2021,
Volume and Issue:
144(15)
Published: Sept. 10, 2021
Among
the
estimated
6.2
million
Americans
living
with
heart
failure
(HF),
≈5%/y
may
progress
to
advanced,
or
stage
D,
disease.
Advanced
HF
has
a
high
morbidity
and
mortality,
such
that
early
recognition
of
this
condition
is
important
optimize
care.
Delayed
referral
lack
in
patients
who
are
likely
derive
benefit
from
an
advanced
evaluation
can
have
adverse
consequences
for
their
families.
A
2-step
process
be
used
by
practitioners
when
considering
patient
consideration
therapies,
focused
on
recognizing
clinical
clues
associated
D
assessing
potential
benefits
center.
Although
often
referred
center
undergo
therapies
as
transplantation
implantation
left
ventricular
assist
device,
there
other
reasons
refer,
including
access
infrastructure
multidisciplinary
team
offers
broad
range
expertise.
The
intent
statement
provide
framework
health
systems
help
identify
refer
most
Nature Communications,
Journal Year:
2022,
Volume and Issue:
13(1)
Published: Nov. 14, 2022
Heart
failure
is
a
leading
cause
of
cardiovascular
morbidity
and
mortality.
However,
the
contribution
common
genetic
variation
to
heart
risk
has
not
been
fully
elucidated,
particularly
in
comparison
other
cardiometabolic
traits.
We
report
multi-ancestry
genome-wide
association
study
meta-analysis
all-cause
including
up
115,150
cases
1,550,331
controls
diverse
ancestry,
identifying
47
loci.
also
perform
multivariate
studies
that
integrate
with
related
cardiac
magnetic
resonance
imaging
endophenotypes,
61
Gene-prioritization
analyses
colocalization
transcriptome-wide
identify
known
previously
unreported
candidate
cardiomyopathy
genes
cellular
processes,
which
we
validate
gene-expression
profiling
failing
healthy
human
hearts.
Colocalization,
gene
expression
profiling,
Mendelian
randomization
provide
convergent
evidence
for
roles
BCKDHA
circulating
branch-chain
amino
acids
structure.
Finally,
proteome-wide
identifies
9
proteins
associated
or
quantitative
These
highlight
similarities
differences
among
implicate
pathogenesis
failure,
may
represent
treatment
targets.
Circulation,
Journal Year:
2023,
Volume and Issue:
147(16)
Published: March 21, 2023
Heart
failure
with
preserved
ejection
fraction
(HFpEF)
is
one
of
the
most
common
forms
heart
failure;
its
prevalence
increasing,
and
outcomes
are
worsening.
Affected
patients
often
experience
severe
exertional
dyspnea
debilitating
fatigue,
as
well
poor
quality
life,
frequent
hospitalizations,
a
high
mortality
rate.
Until
recently,
pharmacological
intervention
trials
for
HFpEF
yielded
neutral
primary
outcomes.
In
contrast,
exercise-based
interventions
have
consistently
demonstrated
large,
significant,
clinically
meaningful
improvements
in
symptoms,
objectively
determined
exercise
capacity,
usually
life.
This
success
may
be
attributed,
at
least
part,
to
pleiotropic
effects
exercise,
which
favorably
affect
full
range
abnormalities—peripheral
vascular,
skeletal
muscle,
cardiovascular—that
contribute
intolerance
HFpEF.
Accordingly,
this
scientific
statement
critically
examines
currently
available
literature
on
therapies
chronic
stable
HFpEF,
potential
mechanisms
improvement
capacity
how
these
data
compare
therapy
other
cardiovascular
conditions.
Specifically,
reviewed
herein
demonstrate
comparable
or
larger
magnitude
from
supervised
training
compared
those
reduced
fraction,
although
Medicare
reimbursement
only
latter
group.
Finally,
critical
gaps
implementation
including
setting,
modalities,
combinations
strategies
such
diet
medications,
long-term
adherence,
incorporation
innovative
more
accessible
delivery
methods,
management
recently
hospitalized
highlighted
provide
guidance
future
research.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(17), P. 13111 - 13111
Published: Aug. 23, 2023
Heart
failure
(HF)
is
a
clinical
syndrome
with
high
morbidity
and
mortality,
its
prevalence
rapidly
increasing.
Galectin-3
(Gal-3)
an
important
factor
in
the
pathophysiology
of
HF,
mainly
due
to
role
cardiac
fibrosis,
inflammation,
ventricular
remodeling.
Fibrosis
hallmark
remodeling,
atrial
fibrillation
development.
This
review
aims
explore
involvement
Gal-3
HF
pathogenesis
diagnostic
prognostic
significance.
We
report
data
on
structure
molecular
mechanisms
biological
function
crucial
for
Over
last
decade,
numerous
studies
have
shown
association
between
echocardiographic
CMR
biomarkers
serum
concentration.
discuss
facts
concerns
about
Gal-3's
utility
acute
chronic
preserved
reduced
ejection
fraction
diagnosis,
prognosis,
risk
stratification.
Finally,
we
present
attempts
use
as
therapeutic
target
HF.
